CyGene Laboratories Inc. Announces Product Launch Based on Patented New Product and Service Delivery System.

CORAL SPRINGS, Fla. -- CyGene Laboratories Inc. (OTC:CYGE) ("the Company") announced today that the company has launched its predictive genomics product line based on business model patents it has filed with the U.S. Patent and Trademark Office. The system's flexibility enables a remarkably wide range of distribution for this type of product/service.

Martin Munzer, CyGene's president and CEO, said, "The general sentiment of the public today is positive when it comes to anything having to do with DNA or the human genome project. But most people are not sure how they personally can benefit from the latest developments in this field of science."

CyGene's unique product and service delivery model offers each retail distributor the ability to earn income from subsequent direct sales by the Company to the retailer's original customer. If the customer originally purchases only one test from the retailer and later purchases a second test at a discount through the Company's website, CyGeneDIRECT.com or their fulfillment center 877-693-6232, the retailer will continue to profit by earning a residual income. The patent pending system even provides residual income from referral sales made through the original customer without compromising the anonymity of the consumer.

"This model allows our distributors to enjoy generous profits while educating their customers and allowing them to purchase direct at a discount. In this scenario," said Munzer, "everyone wins."

Potential distributors, retailers, medical clinics, associations, not-for-profit organizations or other entities that are interested in participating in this product launch or would like to learn how they can benefit from this program may contact Pete Laurence, CyGene's VP of Business Development, for additional information. Laurence can be reached at 866-429-4363.

For more information about CyGene Laboratories and its products and technologies, visit the Company's Web site at http://www.CyGeneDirect.com.

About CyGene Direct

CyGeneDirect.com is an online consumer website that provides individuals with education and the opportunity to decide whether generic testing is right for them. Individuals are able to purchase generic test kits from a third party fulfillment center and retrieve their results anonymously in a comprehensive personalized report available on a secure server. The reports help them to understand how their personal genetics affect certain risks, how other factors contribute to their genetic profile and how to modify factors that increase their risk. For more information on CyGene Direct, please visit http://www.cygenedirect.com.

About CyGene Laboratories Inc.

CyGene Laboratories Inc., based in Coral Springs, Florida, is a biotechnology company focused on commercializing genetic and diagnostic testing, as well as developing therapies for infectious, genetic and autoimmune diseases. CyGene's scientific base rests on its Haystack Processing technologies, which it has been developing since 1995. As a result of its work on Haystack Processing, the Company has achieved significant technological breakthroughs that have led to the discovery of its other platform technologies. CyGene believes its patented technologies have promise in the discovery, development and utilization of cutting edge diagnostics based on synthetic DNA and therapeutics based on the rapid clearance of pathogens from the blood. For more information on CyGene Laboratories, Inc., please visit http://www.cygenelabs.com.

Forward-Looking Statements:

The statements made in this news release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Additionally words such as "seek," "intend," "believe," "plan," "estimate," "expect," "anticipate" and other similar expressions are forward-looking statements within the meaning of the Act. Some or all of the results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include, but are not limited to, when or whether the audits of our financial statements will be completed and audit opinions issued, due to unforeseen circumstances or unforeseen issues that may arise during the course of such audits. CyGene Laboratories Inc. has no duty and undertakes no obligation to update such statements. You should independently investigate and fully understand all risks before making investment decisions.